{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:30:30Z","timestamp":1761183030259,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.jiac.2018.12.007","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:20:00Z","timestamp":1548973200000},"page":"273-280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Analysis of synergy between beta-lactams and anti-methicillin-resistant Staphylococcus aureus agents from the standpoint of strain characteristics and binding action"],"prefix":"10.1016","volume":"25","author":[{"given":"Daisuke","family":"Ono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-1890","authenticated-orcid":false,"given":"Tetsuo","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakaze","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayami","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Momoko","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Tojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hinako","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7885-3121","authenticated-orcid":false,"given":"Yoshikazu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6200-6163","authenticated-orcid":false,"given":"Kazuhiro","family":"Tateda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2018.12.007_bib1","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2018.12.007_bib2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/S0140-6736(09)61999-1","article-title":"Community-associated meticillin-resistant Staphylococcus aureus","volume":"375","author":"DeLeo","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2018.12.007_bib3","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1001\/jama.298.15.1763","article-title":"Invasive methicillin-resistant Staphylococcus aureus infections in the United States","volume":"298","author":"Klevens","year":"2007","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.jiac.2018.12.007_bib4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5694\/j.1326-5377.2009.tb02841.x","article-title":"Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand","volume":"191","author":"Turnidge","year":"2009","journal-title":"Med J Aust"},{"key":"10.1016\/j.jiac.2018.12.007_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jiac.2018.12.007_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkr101","article-title":"Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study","volume":"66","author":"Jones","year":"2011","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2018.12.007_bib7","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1093\/cid\/civ534","article-title":"Telavancin: mechanisms of action, in\u00a0vitro activity, and mechanisms of resistance","volume":"61","author":"Karlowsky","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2018.12.007_bib8","doi-asserted-by":"crossref","first-page":"7837","DOI":"10.1128\/AAC.02015-15","article-title":"Reduced in\u00a0vitro activity of ceftaroline by Etest among clonal complex 239 methicillin-resistant Staphylococcus aureus clinical strains from Australia","volume":"59","author":"Abbott","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.12.007_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0034-1396906","article-title":"Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections","volume":"36","author":"Davis","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2018.12.007_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2018.12.007_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13063-016-1295-3","article-title":"CAMERA2 \u2013 combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial","volume":"17","author":"Tong","year":"2016","journal-title":"Trials"},{"key":"10.1016\/j.jiac.2018.12.007_bib12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/47.1.83","article-title":"In\u00a0vitro synergy between cefepime and vancomycin against methicillin-susceptible and -resistant Staphylococcus aureus and Staphylococcus epidermidis","volume":"47","author":"Lozniewski","year":"2001","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2018.12.007_bib13","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1128\/AAC.44.5.1394-1396.2000","article-title":"Vancomycin and oxacillin synergy for methicillin-resistant staphylococci","volume":"44","author":"Domaracki","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"year":"2015","series-title":"M07-A10 \u2013 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","key":"10.1016\/j.jiac.2018.12.007_bib14"},{"year":"2010","series-title":"M100-S20 \u2013 Performance standards for antimicrobial susceptibility testing: 20th informational supplement","key":"10.1016\/j.jiac.2018.12.007_bib15"},{"year":"2017","series-title":"M100-S27 \u2013 Performance standards for antimicrobial susceptibility testing: 27th informational supplement","key":"10.1016\/j.jiac.2018.12.007_bib16"},{"key":"10.1016\/j.jiac.2018.12.007_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF02347736","article-title":"Clinical breakpoints for antimicrobial agents in pulmonary infections and sepsis: report of the committee for Japanese standards for antimicrobial susceptibility testing for bacteria","volume":"1","author":"Atsushi","year":"1995","journal-title":"J\u00a0Infect Chemother"},{"year":"2016","series-title":"The EUCAST Subcommittee on MIC distributions and epidemiological cut-off values (ECOFFs). Discussion document","key":"10.1016\/j.jiac.2018.12.007_bib18"},{"key":"10.1016\/j.jiac.2018.12.007_bib19","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1128\/AAC.40.9.1973","article-title":"Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods","volume":"40","author":"Bajaksouzian","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.12.007_bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.00165-06","article-title":"Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr, and major differences in junkyard regions","volume":"51","author":"Kondo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.12.007_bib21","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00579-09","article-title":"Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements","volume":"53","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.12.007_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.diagmicrobio.2012.07.013","article-title":"Presence of the bla(Z) beta-lactamase gene in isolates of Staphylococcus aureus that appear penicillin susceptible by conventional phenotypic methods","volume":"74","author":"El Feghaly","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2018.12.007_bib23","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1128\/AAC.02354-12","article-title":"Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2018.12.007_bib24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin Infect Dis"},{"year":"2018","series-title":"Vancomycin, BODIPY\u2122 FL Conjugate (BODIPY\u2122 FL Vancomycin) package insert","author":"Invitrogen","key":"10.1016\/j.jiac.2018.12.007_bib25"},{"key":"10.1016\/j.jiac.2018.12.007_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1830477X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1830477X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:58:05Z","timestamp":1761159485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X1830477X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1341321X1830477X"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2018.12.007","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of synergy between beta-lactams and anti-methicillin-resistant Staphylococcus aureus agents from the standpoint of strain characteristics and binding action","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2018.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}